Cellbxhealth Narrows Operating Losses by 60% in Q3 2026 Trading Update

Key Facts

Cellbxhealth announced a 60% reduction in cash operating losses to £4.0 million for the nine months ending September 30, 2026. Benzinga reported that the company secured £0.3 million in new business during the third quarter, a threefold increase compared to the £0.1 million secured in the same period of 2025.

The company expects to deliver full-year 2026 revenues of approximately £1.8 million, representing a 29% year-on-year increase. Cellbxhealth held cash and equivalents of £1.4 million as of September 30, 2026, and anticipates receiving an R&D tax credit of £0.8 million in the coming months. Looking ahead to 2027, management projects revenues in the range of £3.0 million to £4.0 million driven by operational improvements and an expanding pipeline.